The Case for More Aggressive Masking in Psychedelic Trials
Kevin H. Yang, Boris D. Heifets, Andrew D. Krystal, Josh Woolley
JAMA Psychiatry September 16, 2026 DOI: 10.1001/jamapsychiatry.2026.2858 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|
Abstract
This Viewpoint discusses the UMBRAA (unidentifiable multidrug blinding with reduced, authorized awareness) strategy to address the masking problem in psychedelic trials.
Citations in the library
Cites 6
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial Psychological Medicine June 15, 2018
- Addressing blinding in classic psychedelic studies with innovative active placebos. The International Journal of Neuropsychopharmacology April 1, 2025
- Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials. JAMA Psychiatry March 1, 2025
- What should constitute a control condition in psychedelic drug trials? Nature Mental Health October 1, 2024
- Out of control: Blinding, dose response, and psychosocial controls in psychedelic trials Journal of Psychopharmacology September 1, 2025
and 1 more in the library